Tinea Pedis Clinical Trial
Official title:
21-Day Cumulative Irritation Test
Verified date | April 2019 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor.
Status | Completed |
Enrollment | 44 |
Est. completion date | November 2008 |
Est. primary completion date | November 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Subjects must meet all of the following criteria for inclusion in the study. 1. Healthy volunteers of either sex, at least 18 years of age or older. 2. Females must be of non-childbearing potential (i.e., post-menopausal or surgically sterile [bilateral oophorectomy and/or total hysterectomy]). All females must submit to a urine pregnancy test and have a negative result at Day 1 and at the final study visit. 3. Subjects may be of any skin type or race providing their degree of skin pigmentation does not interfere with making readings of skin reactions. 4. Willingness to follow the study procedures and complete the study. 5. Written informed consent obtained. Exclusion Criteria: 1. Any skin disease that would in any way confound interpretation of the study results. Atopic dermatitis/eczema, psoriasis will be excluded. 2. Chronic asthma will be excluded. 3. Pregnant or nursing mothers. 4. A history of sensitivity to any component of any of the formulations. 5. Use of chronic medications (such as antihistamines, corticosteroids, analgesics and anti-inflammatories) for one week before and during the study. |
Country | Name | City | State |
---|---|---|---|
United States | The Education and Research Foundation, Inc. | Lynchburg | Virginia |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Irritation Score (5-point scale) | Daily for 21 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05493488 -
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis
|
Phase 2 | |
Completed |
NCT04883593 -
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
|
Early Phase 1 | |
Terminated |
NCT02842021 -
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
|
Phase 2 | |
Completed |
NCT01712360 -
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
|
Phase 4 | |
Completed |
NCT03676686 -
Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis
|
N/A | |
Completed |
NCT01519752 -
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
|
Phase 1 | |
Completed |
NCT03320486 -
Non-inferiority Trial of Dapaconazole Versus Ketoconazole
|
Phase 3 | |
Completed |
NCT01580891 -
Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
|
Phase 1 | |
Completed |
NCT01349998 -
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
|
Phase 3 | |
Completed |
NCT01353976 -
Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
|
Phase 3 | |
Completed |
NCT04265521 -
Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet
|
N/A | |
Completed |
NCT02633813 -
BE Study of Naftifine HCL
|
Phase 3 | |
Recruiting |
NCT00856596 -
Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females
|
Phase 3 | |
Completed |
NCT00869336 -
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
|
Phase 2 | |
Completed |
NCT00768599 -
A Study of Econazole Foam 1% in Athlete's Foot
|
Phase 2 | |
Recruiting |
NCT00233493 -
Spread of Dermatophytes Among Families
|
N/A | |
Completed |
NCT03897257 -
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
|
Phase 2 | |
Completed |
NCT03129321 -
Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
|
Phase 3 | |
Completed |
NCT02335255 -
Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis
|
Phase 1 | |
Withdrawn |
NCT02606383 -
Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis
|
Phase 3 |